Preparation and characterization of erythrocyte membrane cloaked PLGA/arsenic trioxide nanoparticles and evaluation of their<i>in vitro</i>anti-tumor effect

Su, Jing; Liu, Geyi; Lian, Yumei; Kamal, Zul; Que, Xiao; Qiu, Yajing; Qiu, Mingfeng

doi:10.1039/c8ra01417e

Cited by 26 publications

(17 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rat blood samples were collected into 9NC 0.105M buffered sodium citrate vacuum tubes (BD Vacutainer, Plymouth, UK), centrifuged, and red blood cells were treated with 200 µM, 400 µM, 800 µM, and 1 mM of EV-34 or equimolar concentration of ibuprofen in phosphate buffered saline (PBS). Ultrapure water was used as positive control as it has been described earlier [ 39 , 40 ], while PBS served as the negative control. After mixing the samples gently, each solution was incubated at room temperature for 10 min, and then centrifuged at 5000× g .…”

Section: Methodsmentioning

confidence: 99%

Basic Pharmacological Characterization of EV-34, a New H2S-Releasing Ibuprofen Derivative

et al. 2021

View full text Add to dashboard Cite

Background: Cardioprotective effects of H2S are being suggested by numerous studies. Furthermore, H2S plays a role in relaxation of vascular smooth muscle, protects against oxidative stress, and modulates inflammation. Long-term high-dose use of NSAIDs, such as ibuprofen, have been associated with enhanced cardiovascular risk. The goal of the present work is the synthesis and basic pharmacological characterization of a newly designed H2S-releasing ibuprofen derivative. Methods: Following the synthesis of EV-34, a new H2S-releasing derivative of ibuprofen, oxidative stability assays were performed (Fenton and porphyrin assays). Furthermore, stability of the molecule was studied in rat serum and liver lysates. H2S-releasing ability of the EC-34 was studied with a hydrogen sulfide sensor. MTT (3-(4,5-dimethylthiazol 2-yl)-2,5-(diphenyltetrazolium bromide)) assay was carried out to monitor the possible cytotoxic effect of the compound. Cyclooxygenase (COX) inhibitory property of EV-34 was also evaluated. Carrageenan assay was carried out to compare the anti-inflammatory effect of EV-34 to ibuprofen in rat paws. Results: The results revealed that the molecule is stable under oxidative condition of Fenton reaction. However, EV-34 undergoes biodegradation in rat serum and liver lysates. In cell culture medium H2S is being released from EV-34. No cytotoxic effect was observed at concentrations of 10, 100, 500 µM. The COX-1 and COX-2 inhibitory effects of the molecule are comparable to those of ibuprofen. Furthermore, based on the carrageenan assay, EV-34 exhibits the same anti-inflammatory effect to that of equimolar amount of ibuprofen (100 mg/bwkg). Conclusion: The results indicate that EV-34 is a safe H2S releasing ibuprofen derivative bearing anti-inflammatory properties.

show abstract

Section: Methodsmentioning

confidence: 99%

Basic Pharmacological Characterization of EV-34, a New H2S-Releasing Ibuprofen Derivative

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Lactate dehydrogenase (LDH) is an enzyme that is produced by erythrocytes and can be determined photometrically with the LDH assay kit/ LDH Assay Kit (Colorimetric) (ab102526) [46,47]. The erythrocyte suspension was prepared according to the protocol previously discussed on haemolysis.…”

Section: Evaluation Of Erythrocyte Membrane Integritymentioning

confidence: 99%

Methotrexate-loaded polymeric lipid hybrid nanoparticles (PLHNPs): a reliable drug delivery system for the treatment of glioblastoma

Bhattacharya

2021

Journal of Experimental Nanoscience

View full text Add to dashboard Cite

Polymeric lipid hybrid nanoparticles (PHLNPs) are core-shell nanoparticle structures made up of polymer cores and lipid shells that have properties similar to both polymeric nanoparticles and liposomes. Methotrexate (MTX) loaded PLHNPs containing tween 80, phosphatidylcholine, poly D, L-lactic-co-glycolic acid (PLGA) and glyceryl tripalmitate prepared using solvent injection and homogenisation method for a glioblastoma treatment option. The MTX-loaded PLHNPs optimised by Box-Behnken design to minimise particle size, higher entrapment efficacy and maximise MTX concentration in the brain at 4 h. The particle size, entrapment efficacy, concentration of drug in the brain at 4 h, zeta potential, and AUC (Brain) /AUC (Plasma) ratio were in the range of 173.51-233.37 nm, 70.56-86.34%, 6.38-12.38 lg/mL, 25.78-36.31 mV and 1.02-5.32. In-vitro drug release studies, cellular internalisation of optimised formulation against U-87 MG shows good anticancer effects.

show abstract

“…Lactate dehydrogenase (LDH) is an enzyme that is produced by erythrocytes and can be determined photometrically with the LDH assay kit / Lactate Dehydrogenase Assay Kit (Colorimetric) (ab102526) [42,43]. The erythrocyte suspension was prepared according to the protocol previously discussed on haemolysis.…”

Section: Evaluation Of Erythrocyte Membrane Integritymentioning

confidence: 99%

In-vitro Investigation of Polymeric Lipid Hybrid Nanoparticles (Plhns) Of a Chemotherapeutic Drug for the Treatment of Glioblastoma Multiforme

Bhattacharya¹

2021

Preprint

View full text Add to dashboard Cite

PHLNs (polymeric lipid hybrid nanoparticles) are core–shell nanoparticle structures made up of polymer cores and lipid shells that have properties similar to both polymeric nanoparticles and liposomes. Methotrexate (MTX) loaded PLHNPs containing tween 80, phosphatidylcholine, poly D, L-lactic-co-glycolic acid (PLGA) & glyceryl tripalmitate prepared using solvent injection & homogenization method for glioblastoma treatment option. The MTX loaded PLHNPs optimized by Box–Behnken design to minimize particle size, higher entrapment efficacy, and maximize MTX concentration in the brain at 4h. The particle size, entrapment efficacy, concentration of drug in brain at 4h, zeta potential and AUC(Brain)/AUC(Plasma) ratio were in the range of 173.51-233.37nm, 70.56-86.34%, 6.38-12.38 μg/mL, 25.78-36.31mV & 1.02-5.32. in-vitro drug release studies, cellular internalization of optimized formulation against U-87 MG shows good anticancer effects.

show abstract

Preparation and characterization of erythrocyte membrane cloaked PLGA/arsenic trioxide nanoparticles and evaluation of theirin vitroanti-tumor effect

Abstract: Arsenic trioxide (ATO) is used for acute promyelocytic leukemia (APL) that is resistant to all-trans-retinoic acid, but its direct intravenous injection sometimes induces severe toxic side effects.

Cited by 26 publications

References 33 publications

Basic Pharmacological Characterization of EV-34, a New H2S-Releasing Ibuprofen Derivative

Basic Pharmacological Characterization of EV-34, a New H2S-Releasing Ibuprofen Derivative

Methotrexate-loaded polymeric lipid hybrid nanoparticles (PLHNPs): a reliable drug delivery system for the treatment of glioblastoma

In-vitro Investigation of Polymeric Lipid Hybrid Nanoparticles (Plhns) Of a Chemotherapeutic Drug for the Treatment of Glioblastoma Multiforme

Contact Info

Product

Resources

About